{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:55:52Z","timestamp":1783122952597,"version":"3.54.6"},"reference-count":59,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Covalent Bruton\u2019s tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib, zanubrutinib) improve outcomes in advanced chronic lymphocytic leukemia (CLL) but resistance, largely driven by BTK C481 mutations, and adverse events limit long-term benefit. Noncovalent BTK inhibitors (e.g., pirtobrutinib) reversibly inhibit the BTK ATP-binding pocket independent of C481, potentially overcoming resistance and reducing toxicity. This review summarizes clinical evidence for pirtobrutinib in CLL. Methods: A PubMed search of articles through July 2025 was conducted, focusing on clinical trials of pirtobrutinib. We extracted efficacy, safety, and resistance data, emphasizing the BRUIN CLL-321 phase 3 trial and related studies. Results: Pirtobrutinib demonstrates activity against BTK resistance mutations with a favorable safety profile, partly due to high kinase selectivity. In BRUIN CLL-321, pirtobrutinib achieved an overall response rate (ORR) of 62% and a median progression-free survival (PFS) of 20 months in heavily pretreated patients, including those with resistance mutations. Yet, resistance mechanisms\u2014such as alternative pathway activation and additional BTK mutations\u2014emerge in a subset. Baseline genetic features, including BTK mutation status and cytogenetics, influence response durability and outcomes. Ongoing phase 3 trials comparing pirtobrutinib with covalent BTK inhibitors will clarify its potential as a first-line option and its integration into treatment algorithms. In relapsed\/refractory CLL, noncovalent BTK inhibitors may be incorporated into personalized pathways, including bridging to CAR-T therapy, to optimize long-term disease control. Conclusions: Pirtobrutinib offers a promising strategy to address resistance and potentially improve durable disease control in CLL. Definitive trials will define its role relative to covalent BTK inhibitors and its utility across treatment lines within personalized, multimodal regimens.<\/jats:p>","DOI":"10.3390\/cancers17182974","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T14:23:50Z","timestamp":1757600630000},"page":"2974","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6507","authenticated-orcid":false,"given":"Stefano","family":"Molica","sequence":"first","affiliation":[{"name":"Department Hematology, Hull University Teaching Hospitals NHS Trust, Hull HU3 2JZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-6109","authenticated-orcid":false,"given":"David","family":"Allsup","sequence":"additional","affiliation":[{"name":"Department Hematology, Hull University Teaching Hospitals NHS Trust, Hull HU3 2JZ, UK"},{"name":"Centre for Biomedicine, Hull York Medical School, Hull YO10 5DD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as Initial Therapy for Elderly Patients with Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, Phase 1b\/2 Trial","volume":"15","author":"Furman","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Burger, J.A., Barr, P.M., Robak, T., Owen, C., Tedeschi, A., Sarma, A., Patten, P.E., Grosicki, S., McCarthy, H., and Offner, F. (2025). Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL. Blood, online ahead of print.","DOI":"10.1182\/blood.2024028205"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicenter, randomized, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib Versus Bendamustine and Rituximab in Patients with Treatment-Na\u00efve Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: Second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1080\/10428194.2023.2256911","article-title":"Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia","volume":"64","author":"Huntington","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Am. Soc. Hematol. Educ. Program"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/ajh.27544","article-title":"Prevalence of BTK and PLCG2 Mutations in CLL Patients with Disease Progression on BTK Inhibitor Therapy: A Meta-Analysis","volume":"100","author":"Molica","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"Chem. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1080\/10428194.2025.2466101","article-title":"Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy","volume":"66","author":"Gruessner","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2025053","DOI":"10.4084\/MJHID.2025.053","article-title":"Bruton\u2019s Tyrosine Kinase (BTK) Mutations in Chronic Lymphocytic Leukemia (CLL): A Clinical View","volume":"17","author":"Molica","year":"2025","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_24","first-page":"62","article-title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bravo-Gonzalez, A., Alasfour, M., Soong, D., Noy, J., and Pongas, G. (2024). Advances in Targeted Therapy: Addressing Resistance to BTK Inhibition in B-Cell Lymphoid Malignancies. Cancers, 16.","DOI":"10.20944\/preprints202407.1534.v1"},{"key":"ref_26","first-page":"3137","article-title":"Pirtobrutinib: A new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders","volume":"141","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood.2024026672","article-title":"Novel mechanisms of resistance in CLL: Variant BTK mutations in second-generation and noncovalent BTK inhibitors","volume":"145","author":"Tam","year":"2025","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","article-title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance","volume":"7","author":"Naeem","year":"2023","journal-title":"Blood. Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","article-title":"Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia","volume":"12","author":"Aslan","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_32","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: Results of the phase I\/II BRUIN trial","volume":"110","author":"Shah","year":"2025","journal-title":"Haematologica"},{"key":"ref_33","first-page":"1866","article-title":"Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: A matching-adjusted indirect comparison","volume":"109","author":"Jen","year":"2024","journal-title":"Haematologica"},{"key":"ref_34","first-page":"494","article-title":"Choosing between CAR T-cell therapy and pirtobrutinib in double-refractory CLL","volume":"22","author":"Rogers","year":"2024","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1080\/10428194.2025.2482132","article-title":"Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"66","author":"Jain","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: Final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III Trial of Pirtobrutinib Versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_38","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014A primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/17474086.2023.2271170","article-title":"Redefining efficacy and safety endpoints for chronic lymphocytic leukemia in the era of targeted therapy","volume":"16","author":"Molica","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2024-194748","article-title":"Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton\u2019s Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: Analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda","year":"2024","journal-title":"Lancet Haematol"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/hematology.2023000442","article-title":"Richter transformation-is there light at the end of this tunnel?","volume":"2023","author":"Eyre","year":"2023","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17474086.2025.2469719","article-title":"Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia","volume":"18","author":"Molica","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/hematology.2021000234","article-title":"Is there a role for anti-CD20 antibodies in CLL?","volume":"2021","author":"Shah","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9775","DOI":"10.1038\/s41598-023-36279-x","article-title":"Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: A meta-analysis","volume":"13","author":"Nguyen","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood.2024024510","article-title":"Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: The phase 1b BRUIN trial","volume":"144","author":"Roeker","year":"2024","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/bloodadvances.2022008955","article-title":"Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors","volume":"7","author":"Qi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood-2023-180143","article-title":"Genomic evolution and resistance during pirtobrutinib therapy in covalent BTK-inhibitor (cBTKi) pretreated chronic lymphocytic leukemia patients: Updated analysis from the BRUIN study [abstract]","volume":"142","author":"Brown","year":"2023","journal-title":"Blood"},{"key":"ref_49","first-page":"rs-6249480","article-title":"Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression","volume":"3","author":"Gandhi","year":"2025","journal-title":"Res. Sq."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Shadman, M., and Davids, M.S. (2025). How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor. Blood, online ahead of print.","DOI":"10.1182\/blood.2024025482"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Molica, S., and Allsup, D. (2025). Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors. Cancers, 17.","DOI":"10.3390\/cancers17010119"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jha2.1013","article-title":"Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy","volume":"5","author":"Lamanna","year":"2024","journal-title":"EJHaem"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11864-025-01339-z","article-title":"Covalent and Non-Covalent BTK Inhibition in Chronic Lymphocytic Leukemia Treatment","volume":"26","author":"Shah","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17474086.2024.2366534","article-title":"Defining treatment success in chronic lymphocytic leukemia: Exploring surrogate markers, comorbidities, and patient-centered endpoints","volume":"17","author":"Molica","year":"2024","journal-title":"Expert Rev. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2024-194839","article-title":"Efficacy and Safety of the Bruton\u2019s Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a\/b Study","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/2974\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:54Z","timestamp":1760035434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/18\/2974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":59,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cancers17182974"],"URL":"https:\/\/doi.org\/10.3390\/cancers17182974","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}